Early assets offer significant promise for targeting new avenues to treat disease in ways that have yet to be tapped by established companies. However, a molecule that hits a target may still carry significant discovery and development risks. In this panel, experienced entrepreneurs, pharma developers and service providers will discuss the challenges of bridging the gap between early promise and clinic-ready compound, provide guidance on considerations would-be entrepreneurs need to convince the all too important investors that they have derisked their programs as much as possible and share case studies of successes and failures. Learn from experienced entrepreneurs and drug hunters alike in this lively panel.

Ability Level: All

Session ID: 21155